Clinical Trial Details
— Status: Suspended
Administrative data
| NCT number |
NCT03909867 |
| Other study ID # |
IRB00056852 |
| Secondary ID |
|
| Status |
Suspended |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 17, 2021 |
| Est. completion date |
September 2025 |
Study information
| Verified date |
March 2024 |
| Source |
Wake Forest University Health Sciences |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The purpose of this observational study is to describe the environmental aerosolization
patterns burden of RSV in the air and on surfaces in surrounding adult patients in a
real-life setting. Specific objectives are to determine the particle size distribution and
the quantity of airborne pathogens dispersed by symptomatic participants, to establish a
spatial model of airborne emission and subsequent surface burden of RSV emission and
dispersal in clinical settings (emergency department and inpatient units; 1 foot vs. 3-6 feet
vs. 8-10 feet), and to obtain information regarding the potential association of illness
severity and risk factors to the scale of airborne dispersal (e.g., super spreaders). This
study will be used to collect data of the emission patterns of RSV. Subsequent investigations
will help guide policymakers in the assessment of the airborne exposure risk to RSV and the
implementation of appropriate infection prevent measures such as respirators and face masks.
The investigators hypothesize that the airborne emission patterns of Respiratory Syncytial
Virus varies between individual patients. The investigators are proposing to assess the
particle size and spatial distribution of airborne RSV emitted by affected patients within a
routine care environment:
1. Characterize individuals who develop respiratory illnesses caused by RSV in terms of
demographics, co-morbid conditions, prior vaccinations (e.g., influenza vaccine, DTAP),
use of antivirals, and severity of illness (fever, respiratory symptoms, malaise).
2. Determine the particle size distribution patterns and quantities of the pathogen in two
settings, an emergency department and an inpatient unit (ICU and non-ICU settings).
3. Establish a spatial model (1 foot vs. 3-6 feet vs. 8-10 feet) of airborne pathogen
dispersal and subsequent surface burden in two settings, an emergency department and an
inpatient unit (ICU and non-ICU settings).
4. Determine the correlation between the human aerosolization patterns and the severity of
illness (fever, respiratory symptoms, malaise) in individual participants (super
spreader?).
Description:
Research Design and Methods The main objective of this study is to identify and determine
airborne emission and subsequent surface burden patterns of RSV in naturally infected
patients.
Patient Information:
Patients seen at the Emergency Department( ED) or admitted to the hospital with respiratory
symptoms and diagnosed with RSV are eligible for enrollment. The results of routine in-house
laboratory diagnostic tests such as the Respiratory Viral Panel (RVP) will be used to
identify patients.
Setting:
Wake forest baptist medical center (WFBMC) is an 885 bed tertiary care teaching hospital.
There are approximately 36,000 inpatient admissions and >89,000 ED visits annually
(pediatric/adult). Air sampling is conducted in patient rooms under turbulent airflows (6
total air changes/hour) at approximately 20°C temperature and 40% Relative Humidity. Air is
filtered by ANSI/ASHRAE 52.2 compliant endfilters with a minimum efficiency reporting value
of 15.
Sampling:
One nasopharyngeal swab will be obtained from each subject. The sample will be used to
confirm RSV infection and determine the amount of the pathogen carried by the individual.
Samples will be inoculated into Becton Dickinson Universal Viral Transport System (VTM, BD
Diagnostics, Franklin Lakes, NJ) for real-time reverse transcriptase PCR (rRT-PCR) analysis.
One-time air samples will be collected using six-stage Andersen air sampling devices and
settle plates at three locations, head of bed/chair two feet away from patient head, foot of
bed/chair eight feet away from head, and at the exit of the patient room (11):
Samples will be collected in viral transport media (VTM), supplemented with RNA stabilization
buffer (Qiagen AVL buffer) and carrier RNA and then stored at -80C. Carrier RNA will serve as
both a carrier and an internal control by containing genomic RNA of the plant tobacco mosaic
virus. A 540 ul volume of RNA sample will be purified with the QIAmp Viral RNA Mini
Extraction Kit and concentrated approximately 10-fold. RSV serotypes A and B as well as the
control viral tobacco mosaic virus RNA will be detected by reverse transcription and
quantitative PCR. Additionally, nNasopharyngeal swab with also be used for cultures with
inoculation in petri dish containing RSV specific media.
The surface burden of RSV will be assessed by placement of open standard Petri dishes filled
with VTM at the three air sampling locations. The covers of the Petri dishes will be removed
at the beginning of and closed after the air sampling session. Selected environmental
surfaces will be sampled with sterile swabs moistened with VTM or TSB broth. A two square
inch area will be swabbed once at three high-touch locations daily: head of the bed hand
rail, middle of food tray table, and a table/horizontal surface at back of room
(approximately 10 feet away past foot of bed). The swabs will be vortexed for 30 seconds, and
processed as described for RSV detection in air samples.
During the sampling health care professional (HCP) and study staff will wear respirators
(N-95) to reduce the risk of external contamination due to potential RSV carrier status. The
respirators will be collected and a two square inch midsection of the respirator will be cut
out using sterile scissors. The cut-outs are placed in 2mLs VTM or TSB broth and frozen.
After thawing, samples are vortexed/agitated, and further processed as described for the RSV
samples.
